StockIQpro
NASDAQ:IMRX

Immuneering Corp

Track all markets on TradingView
Track all markets on TradingView

Immuneering Corp reported net income of −$56.0M in fiscal 2025. Free cash flow was −$45.5M, and the diluted share count rose 46.8%.Summary generated from Immuneering Corp's SEC filings. Latest annual report filed Mar 6, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−43.1%
Debt / equityn/a
Free cash flow−$45.5M
FCF marginn/a
Share count change+46.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue200n/an/a
Operating income−34−52−58−64−59
Net income−34−51−53−61−56
Free cash flow−31−45−49−55−45

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations